Keros Therapeutics Announces Strategic Collaboration with Healey & AMG Center for ALS to Advance Rinvatercept in ALS Clinical Trials

Key Highlights for Investors

• Keros Therapeutics (Nasdaq: KROS) has entered into a pivotal agreement with Massachusetts General Hospital (MGH) to evaluate its lead asset, rinvatercept, in patients with amyotrophic lateral sclerosis (ALS) as part of the Healey ALS MyMatch program.
• The ALS MyMatch program, led by the Sean M. Healey & AMG Center for ALS at Mass General Brigham, is an innovative, biomarker-driven clinical trial platform designed to accelerate the development of new therapies for ALS.
• Rinvatercept will be studied in a Phase 2 clinical trial targeting ALS patients, with the goal of preserving muscle strength and function and improving quality of life.
• The collaboration reflects Keros’s selection in response to the Healey & AMG Center’s competitive call for applications, underscoring scientific validation and external recognition of rinvatercept’s potential.

Details of the Collaboration and Clinical Development

Keros Therapeutics, a clinical-stage biopharmaceutical company specializing in therapies that target dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins, has announced a significant collaboration with Massachusetts General Hospital. The partnership aims to design and implement a Phase 2 clinical trial evaluating rinvatercept in ALS patients, specifically within the framework of the Healey ALS MyMatch program.

The ALS MyMatch program is a groundbreaking initiative that leverages comprehensive genetic and biofluid biomarkers to match subgroups of ALS patients with experimental therapies best suited to their disease profile. By focusing on biomarker-driven, personalized approaches, the program aims to improve the efficiency and relevance of early-stage clinical trials (Phase 1b/2a), helping to identify the optimal patient populations for subsequent larger trials.

According to Keros’s President and CEO, Jasbir S. Seehra, Ph.D., “Rinvatercept represents a potentially novel approach to treat patients with ALS. Based on the data we have generated to date, we believe there is a strong scientific rationale for the potential of rinvatercept to preserve muscle strength and function and improve quality of life in patients with ALS.” This strong endorsement from Keros’s leadership highlights the company’s confidence in the therapeutic’s mechanism of action and clinical promise.

Dr. Merit Cudkowicz, Director of the Healey & AMG Center for ALS, remarked, “ALS is a serious, progressive disorder with need of additional treatment options. We look forward to partnering with Keros to evaluate rinvatercept within the ALS MyMatch program, bringing us closer to our goal of finding additional treatments for those battling ALS.”

Program and Product Details

About Healey ALS MyMatch

Healey ALS MyMatch is a multi-site, collaborative initiative currently operating across leading ALS research centers: Mass General in Boston, University of Minnesota in Minneapolis, Northwestern University in Evanston, and Nova Southeastern University in Fort Lauderdale. It is an affiliate of the Network of Excellence for ALS (NEALS) and partners with the Acceleration Centers of Enrollment (ACE) program, which accelerates trial startup and recruitment. The program’s expansion is anticipated as additional high-performing sites are added.

About Rinvatercept

Rinvatercept is a novel ligand trap, comprised of a modified ligand-binding domain from activin receptor type IIA and type IIB, fused to the Fc domain of human antibody. It is designed to inhibit the biological effects of myostatin and activin A—key regulators that limit muscle and bone mass and strength. Preclinical and early clinical data suggest rinvatercept may promote muscle regeneration, increase muscle size and strength, inhibit fibrosis and inflammation, reduce fat accumulation, and improve bone health. The drug is currently being developed for both Duchenne muscular dystrophy and ALS.

About Keros Therapeutics

Keros is a leader in the TGF-β space, developing therapeutics for a range of disorders involving muscle, bone, cardiovascular, adipose, and hematologic tissues. Its lead product candidates are rinvatercept (for ALS and Duchenne muscular dystrophy) and elritercept (for cytopenias in myelodysplastic syndrome and myelofibrosis).

Potential Impact and Price-Sensitive Information

• Selection for the Healey ALS MyMatch program is a significant validation of the scientific rationale for rinvatercept and its potential to address a high unmet need in ALS—a rapidly progressive, fatal neurodegenerative disease with limited treatment options.
• The collaboration with Mass General Brigham, a world-renowned research hospital, may enhance Keros’s credibility, visibility, and partnership potential in the biotech sector.
• Successful clinical results in ALS could represent a large market opportunity and a transformational catalyst for Keros’s valuation, potentially driving significant shareholder value.
• Positive data or regulatory milestones from this trial could be highly price sensitive, given the limited pipeline for ALS drugs and the growing interest in disease-modifying therapies for orphan/rare diseases.
• Investors should be aware of risks related to clinical development, regulatory hurdles, and Keros’s dependence on successful advancement of its pipeline. Any setbacks or delays could negatively impact the share price.

Forward-Looking Statements and Disclosure

This update contains forward-looking statements, including the potential efficacy and impact of rinvatercept, the progress of clinical trials, and the future prospects for regulatory approval and commercialization. These statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those anticipated. Please refer to Keros Therapeutics’ filings with the SEC for a detailed discussion of these risks, including its most recent Form 10-K and subsequent reports.

Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Investors are encouraged to conduct their own due diligence and consult with a financial advisor before making investment decisions.

View Keros Therapeutics, Inc. Historical chart here